medic suppli devic
med-tech matchmak deal idea
messag med-tech activ somewhat sluggish fewest
transact announc across sector sinc total deal valu
come second straight year vs believ
slowdown least partial attribut gener healthi fundament across
large-cap group elev valuat publicli trade small-cap med-tech
compani rich multipl cap curv remain potenti hurdl
increas deal activ large-cap med-tech balanc sheet remain rel
healthi today sever manag team signal willing deploy
capit right opportun come along spirit valentin day
report play matchmak analyz five hypothet pair believ could
make sens strateg perspect
note transact mention strictli hypothet
knowledg strateg discuss current underway assign
probabl consumm detail accretion/dilut calcul
assumpt avail upon request
get year deal let look back amid broader med-tech
 lull last year five list compani acquir deal privat
compani domin action total privat compani bought public
med-tech player nearli match record pace fact privat
compani takeov across sector eclips total prior five
year combin despit dearth public-for-publ transact one propos
matchmak target acquir second straight year read full
matchmak report deal
boston leverag urolog leadership stimul neuromod growth
singl biggest share gainer neuromodul past two year
grow above-market clip establish leader db follow
 launch one segment compani doesnt particip today sacral
nerv modul market recent entir
chang septemb fda approv rsnm system design
address mani histor shortcom interstim devic expect
launch axon system along next-gen interstim micro devic drive
acceler snm market growth similar saw segment
boston alreadi call mani physician perform snm implant
urolog franchis buy axon would allow boston leverag lead
presenc urologist strengthen neuromodul franchis time
mani competitor launch innov new product across
db segment
zimmer goe superson sinc take ceo late bryan hanson
stress need upgrad compani wamgr branch higher
growth adjac process two year later yet get underway
howev base busi show sign meaning improv cours
believ compani could turn attent strateg capit deploy
see type asset zimmer consid evalu
potenti deal ad flagship bonescalpel devic bag would give zimmer
new growth driver within exist busi like spine cranial oral maxillofaci
surgeri compani presenc today gener grown below-market
rate past year meanwhil mson broader portfolio could help zimmer
establish beachhead market like plastic wound care gener surgeri also
see potenti synergi zimmer rosa robot surgeri system design
facilit accur cut ultrason oscil technolog
help execut
page analyst certif import disclosur
abbott patch lag ep franchis larg sat sidelin
 play field digest st jude aler deal
time compani aggress paid debt reduc leverag ratio
process incom ceo robert ford indic
hurri deploy excess balanc sheet capac surpris
see abbott re-engag busi develop front one area abbott
could look supplement electrophysiolog busi although ep one
compani consist medic devic growth segment past three
year abbott consist under-perform vs market leader period
meanwhil abt structur heart pipelin also tie treatment atrial fibril
manag target fda approv amulet laa closur system
better afib diagnosi essenti feed growth opportun
long- erm someth could help ad irhythm zio could enabl abbott
build full-servic platform around diagnosi treatment afib perhap steer
patient therapi option process combin zio
confirm rx implant cardiac monitor would also round arrhythmia detect
portfolio final see potenti synergi data analyt capabl
roch sens opportun cgm roch leader global diabet
technolog market sale yet exit insulin pump market
roch busi matur sbgm segment mix
caus compani miss growth broader market roch busi
declin four past five year even pump continu grow healthi
clip cgm adopt explod roch dip toe cgm market
ou distributor eversens implant cgm system although result
partnership somewhat underwhelm date also struggl
make headway eversens domest market access issu slow initi
roll-out compani made substanti progress reimburs front
feedback get patient appeal implant system remain
encourag question move whether senseon execut
opportun ultim put eversens hand larger organ may help
unlock potenti roch acquir alreadi could
leverag exist diabet sale infrastructur spread increment launch
cost much larger revenu base model call world-wide cgm sale
top even nich share posit could translat meaning growth driver
meanwhil addit in-hous cgm program could also help roch becom
competit pump market shift toward autom insulin deliveri system
pump cardio busi recent upgrad made
case meaning revenu growth acceler compani yet
outlook organ growth strong time view
also expect activ front go forward geoff martha
take ceo bulk activ like involv small tuck-in deal list
possibl target scale move needl might also
make strong strateg sens rel short one compani believ check
box impella growth slow sharpli past five quarter
amid concern safeti profil question clinic util compar
altern hemodynam support option think dataset spawn
controversi methodolog flaw also believ may ultim need
gener level evid put concern rest process compani
begun could take sever year play meantim howev impella
remain larg highli profit revenu stream could still accret
top bottom line even growth stabil fraction
former level believ deal could work multipl level strateg perspect
well ad impella portfolio would give stronger foothold complex
pci potenti pull sale stent intervent tool process
meanwhil influx engin talent could help resuscit
medtron struggl busi cede point world-wide share
page analyst certif import disclosur
med-tech pick back
med-tech activ somewhat sluggish fewest
transact announc across sector sinc total deal valu come
second straight year vs case
slowdown attribut compani still digest prior deal work
intern issu believ gener healthi fundament across
large-cap group elev valuat publicli trade small-cap med-tech compani
like dampen activ well second year row acquir focus
smaller tuck-in asset privat compani domin list target publicly-
trade compani seller med-tech deal
prior decad besid caus would-b buyer balk valuat
rich multipl assign mani attract small-cap med-tech name also
encourag privat compani seek public exit total med-tech ipo
rais gross offer proce
figur med-tech target type
could see valuat remain issu
compani smid-cap med-tech index trade averag ntm sale today
that high late remain well
averag also slightli averag takeout multipl ntm sale
paid small-cap med-tech deal past decad time mako
mazor acquir forward revenu averag high-growth name
index top-lin compound-annual-growth-rate current trade ntm sale mean mani
attract stori like price seriou consider target
despit challeng backdrop one factor believ work favor
increas activ ampl balanc sheet capac figur show
averag debt/ebitda ratio across mid-to-larg cap compani includ
analysi stand today net basi that roughli flat year
ago sever compani made progress pay debt
lever current carri
leverag ratio rest sector net basi
page analyst certif import disclosur
large-cap compani potenti firepow
undergo leadership chang incom abbott ceo robert
ford indic compani confer call look
deal right geoff martha said capit alloc prioriti
take rein elsewher zimmer manag team talk
call strong enough financi oper posit get
back game even boston earli stage pay
extra debt took part last year btg deal indic could
still alloc tuck-in deal year given improv cash flow significantli
reduc legal liabil go forward result return level probabl
unrealist think could year activ least par
saw
methodolog report lay five deal believ make sens
strateg perspect note transact mention strictli
hypothet knowledg discuss current underway
assign probabl consumm also take stanc
specif fair valu target compani take-over scenario rather
assum rang base averag premium multipl paid past transact
small-cap deal appli premium target last close
price base averag premium paid compar transact
past decad larger deal assum multipl ltm ep
approxim rang similar transact sinc keep thing simpl also
assum transact close decemb base estim
current factset consensu forecast non-cov compani detail
accretion/dilut calcul assumpt avail upon request
page analyst certif import disclosur
boston leverag urolog leadership
boston scientif singl biggest share gainer neuromodul
past two year grow above-market clip spinal cord stimul establish
leader deep brain stimul follow launch one segment
compani doesnt particip today sacral nerv modul urinari fecal
incontin world-wide market recent entir
world-wide snm sale risen compound-annual-growth-rate sinc physician weve
spoken expect growth acceler driven wave new product
innov similar observ space follow fda
approv nevro senza system sale rose compound-annual-growth-rate
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
case entranc new competitor push snm
technolog anoth level axon receiv fda approv use rsnm system
treat fecal incontin septemb overact bladder urinari retent
indic follow novemb compani rsnm devic recharg
system lifespan contrast medtron interstim ii primari cell
system last year averag must replac believ bulki
size need frequent follow-up surgeri due rapid batteri deplet
histor impedi snm adopt remain quit low today
penetr despit receiv approv origin interstim devic
lead prevent migrat intuit physician programm simpl
discret patient control featur design improv user experi
provid patient final rsnm devic constant current system adjust
therapi time base chang electr imped caus
format scar tissu rather constant voltag like interstim ii accord
axon result consist nerv stimul superior long-term
page analyst certif import disclosur
respond new competit threat innov
target fda approv new interstim micro devic next month
micro includ mani advanc axon rsnm includ small
recharg batteri constant current stimul compani also
continu market interstim ii patient prefer recharge-fre option system
expect full-bodi mri label use either imag system
receiv ce mark interstim micro interstim surescan mri lead last
month manag expect launch product domest spring
boston scientif alreadi call mani physician perform snm
implant urolog franchis compani urolog sale rose
expect segment post double-digit growth next year
driven collect new growth driver boston acquir includ
augmenix absorb hydrogel prostat radiotherapi rezum system treatment
bph cytuiti cathet ovarian cancer diagnosi boston also ad
neuromodul divis recent acquisit vertiflex superion
interspin spacer lumbar stenosi buy axon would allow boston leverag
lead presenc urologist strengthen neuromodul
franchis time mani competitor launch innov new product
across db segment
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
estim acquisit would roughli break-even boston
year gener assum purchas price
repres premium tuesday close base averag premium
compar transact would larg deal boston digest
given current balanc sheet capac would valu axon rel full
sale believ financi return would still attract especi given
strong strateg fit estim deal would boost boston organ revenu
growth rate meanwhil math suggest acquir
axon would add boston ep increas ep compound-annual-growth-rate
page analyst certif import disclosur
sinc take ceo zimmer biomet late bryan hanson stress
need upgrad compani weight averag market growth rate wamgr
branch higher growth adjac two year later howev
portfolio upgrad process yet get underway believ delay due mostli
manag desir stabil base busi prior ad anoth layer
complex goal achiev qualiti remedi
warsaw north facil latter stage product suppli normal organ revenu
growth acceler past five quarter zimmer under-perform vs
broader recon market narrow see figur weve written previous see
believ piec place drive multi-year growth acceler
model call organ revenu growth improv
suggest us compani could turn attent
strateg capit deploy look supplement improv core
busi kick next phase turnaround mr hanson suggest much
call say see attract target meet strateg financi filter
may decid invest capit
one factor remain potenti limit zimmer balanc sheet
compani paid debt past three year ebitda also
declin period net result leverag ratio exit
isnt much lower end despit lack
progress think zimmer closer meaning balanc sheet flexibl
may appear model call free cash flow ramp
zimmer continu alloc cash primarili debt paydown estim
could drop leverag ratio less exit would repres
worthwhil target view think compani could creat valu elong
debt paydown timelin begin process diversifi new market
could rais ceil long-term growth trajectori beyond underli
improv alreadi project
page analyst certif import disclosur
see type asset zimmer consid evalu
potenti deal built busi around proprietari ultrason
oscil technolog flagship bonescalpel product design precis cut bone
minim necrosi burn inflamm unnecessari bone loss
instrument tip move oscil per second quickli pass bone
leav elast structur like healthi tissu ligament undamag compani
also adapt technolog tumor remov sonastar wound debrid
sonicon recent launch nexu consol provid all-in-on platform
power entir instrument portfolio septemb complet
acquisit privately-held solsi medic theraskin human skin allograft nearli
doubl revenu base expand presenc wound care space
buy would give zimmer new growth driver exist busi
provid foothold sever attract adjac bonescalpel primarili
use today spine cranial oral maxillofaci surgeri area zimmer
presenc today gener grown market rate past year
meanwhil mson broader portfolio could help zimmer establish beachhead market
like plastic wound care gener surgeri also see potenti synergi
zimmer rosa robot surgeri system design facilit accur cut
ultrason oscil technolog help execut final
believ plug product zimmer distribut network could lead
meaning revenu synergi particularli oversea mson current presenc
limit
estim acquisit could add zimmer ep
gener assum purchas price
premium tuesday close base averag premium paid
compar transact past ten year impli multipl
sale estim zimmer could financ transact size cash hand
exist credit facil without jeopard abil continu retir senior
note matur next year deal would add
compani overal top-lin growth rate math meanwhil
neutral ep year estim acquisit would add zimmer
ep lift earn compound-annual-growth-rate process
page analyst certif import disclosur
abbott larg sat sidelin play field digest
st jude aler deal time compani aggress paid debt
reduc leverag ratio process recent convers
investor increas balanc sheet flexibl led question whether
incom ceo robert ford could kick tenur reengag busi
develop front mr ford threw cold water idea call
said he look deal right cours shouldnt taken
gospel outgo ceo mile white long success histori
dealmak similarli dismiss possibl public comment ahead
mani compani biggest transact
one area abbott could look supplement electrophysiolog busi ep
ablat one best med-tech market past decad grow
compound-annual-growth-rate sinc global sale st jude earli recogn magnitud
atrial fibril opportun sinc acquir compani abbott
benefit strong posit market yet ep one abbott
consist medic devic growth segment past three year busi
consist under-perform vs market leader abt/stj grow slower
pace one past quarter sinc abbott cede
world-wide market share abbott seek address under-perform intern
upgrad ablat cathet portfolio although meaning progress
elsewher compani structur heart pipelin also tie treatment
atrial fibril result amulet trial could present later year
set abbott potenti fda approv entranc left atrial
appendag closur market built global laac
franchis around watchman devic believ market ampl headroom
futur growth penetr increas within warfarin-elig popul
among patient chronic anticoagul regimen poor fit either
complianc concern suscept bleed
page analyst certif import disclosur
better afib diagnosi essenti feed growth opportun
long term someth help sinc ipo compani built
busi around zio wearabl biosensor proprietari data analyt
capabl driven deep neural network train hundr million hour
curat ecg quickli accur diagnos arrhythmia time irhythm
grown sale compound-annual-growth-rate yet compani made signific progress
zio still prescrib small fraction patient suffer afib
symptom meanwhil septemb compani announc partnership verili
develop tool target even larger asymptomat popul despit strong
momentum busi share lag broader market sinc march
vs russel amid investor concern potenti zio
reimburs cut transit categori code categori
period stock multipl compress ntm sale provid
view interest opportun potenti acquir
ad zio could enabl abbott build full-servic platform around diagnosi
treatment atrial fibril perhap steer patient
therapi option process combin zio confirm rx implant cardiac
monitor would also round arrhythmia detect portfolio confirm quickli took
 icm market follow fda approv abbott
momentum stall competit way boston expect
launch lux-dx devic around middl year final see potenti synergi
irhythm data analyt capabl abbott cardiomem heart failur
monitor system grew could see signific
growth reimburs place start
estim acquisit could boost abbott ep growth
gener assum purchas price
premium tuesday close base averag premium paid compar
transact past ten year impli multipl sale
deal would add abbott overal top-lin growth math
would like modestli dilut year believ sale irhythm spend
sg today could rapidli cut compani integr abt exist ep
sale infrastructur estim deal would add abbott ep
lift earn compound-annual-growth-rate process
page analyst certif import disclosur
